Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the … Read more
Rallybio Corp (RLYB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.104x
Based on the latest financial reports, Rallybio Corp (RLYB) has a cash flow conversion efficiency ratio of -0.104x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.55 Million) by net assets ($63.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rallybio Corp - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Rallybio Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rallybio Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rallybio Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHAPEL DOWN GRP PLC LS-05
F:1U6
|
N/A |
|
Chen Nan Iron Wire Co.,Ltd
TWO:2071
|
0.054x |
|
AB Klaipedos nafta
F:XIC
|
0.257x |
|
Precot Limited
NSE:PRECOT
|
0.013x |
|
Nahar Spinning Mills Limited
NSE:NAHARSPING
|
0.216x |
|
Arena Bilgisayar Sanayi ve Ticaret AS
IS:ARENA
|
0.621x |
|
Phenom Resources Corp
OTCQX:PHNMF
|
-0.007x |
|
Cosmax Nbt Inc
KQ:222040
|
0.073x |
Annual Cash Flow Conversion Efficiency for Rallybio Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Rallybio Corp from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $61.65 Million | $-49.28 Million | -0.799x | -40.84% |
| 2023-12-31 | $106.18 Million | $-60.27 Million | -0.568x | -67.75% |
| 2022-12-31 | $169.32 Million | $-57.28 Million | -0.338x | -30.48% |
| 2021-12-31 | $175.60 Million | $-45.53 Million | -0.259x | -60.01% |
| 2020-12-31 | $136.00 Million | $-22.04 Million | -0.162x | +81.82% |
| 2019-12-31 | $16.86 Million | $-15.03 Million | -0.891x | -- |